- Home
- GCTS.WS vs SCNX Comparison
GCTS.WS vs SCNX Comparison
Compare GCTS.WS & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GCTS.WS
GCT Semiconductor Holding Inc. Warrants each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
Current Price
Current Price
Company Overview
Basic Information| Metric | GCTS.WS | SCNX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Other Pharmaceuticals |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 16.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GCTS.WS | SCNX |
|---|---|---|
| Price | $0.24 | $3.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.5K | ★ 34.7K |
| Earning Date | N/A | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $743.36 |
| Revenue Next Year | N/A | $325.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.21 | $2.64 |
| 52 Week High | $0.24 | $106.25 |
Technical Indicators
Market Signals| Indicator | GCTS.WS | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.84 |
| Support Level | N/A | $2.64 |
| Resistance Level | N/A | $3.68 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 0.00 | 43.27 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.